Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)

v3.24.2.u1
Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Accounts Payable and Accrued Expenses    
Accounts payable $ 8,934 $ 6,322
Accrued research and development 1,606 4,118
Accrued compensation 778 2,838
Other 1,872 739
Total accounts payable and accrued expenses 13,190 $ 14,017
Accrued consideration for the uBriGene Asset Purchase Agreement $ 1,400